<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05038124</url>
  </required_header>
  <id_info>
    <org_study_id>21-216</org_study_id>
    <nct_id>NCT05038124</nct_id>
  </id_info>
  <brief_title>A Study of Stereotactic Body Radiotherapy (SBRT) and Surgical Stabilization for People With Cancer That Has Spread to the Bone</brief_title>
  <official_title>A Pilot Study to Assess the Safety and Efficacy of Preoperative Stereotactic Body Radiotherapy for the Treatment of Metastatic Disease in Bone Requiring Surgical Stabilization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the safety of stereotactic body radiation therapy (SBRT)&#xD;
      followed by surgical stabilization within 1 week. All participants will have metastatic&#xD;
      cancer in the bone (bone metastases), and they will be at risk of pathologic fracture (broken&#xD;
      bone caused by a disease). Another purpose of this study is to see if the treatment approach&#xD;
      of SBRT followed by surgical stabilization within 1 week prevents cancer from returning to&#xD;
      the bone.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 30, 2021</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This is a pilot study to evaluate the safety of preoperative stereotactic body radiotherapy (SBRT) with short-interval surgical stabilization.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>risk of major wound complications</measure>
    <time_frame>6 weeks after preoperative SBRT</time_frame>
    <description>Major wound complications are defined as reoperation for wound revision, clinically diagnosed surgical site infection, readmission for wound care, or prolonged (&gt;3 weeks postoperatively) active wound care.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>rate of local control</measure>
    <time_frame>1 year</time_frame>
    <description>Failure of local control is defined as a new lesion within the radiation or surgical field, significant progression of an existing lesion, or reoperation or reirradiation due to tumor progression.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">34</enrollment>
  <condition>Metastatic Cancer</condition>
  <arm_group>
    <arm_group_label>Preoperative Stereotactic Body Radiotherapy (SBRT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Target lesions will be treated with preoperative SBRT consisting of biologically effective dose (BED10) of 50.4 - 81.6 Gy delivered in either three fractions or a single fraction. Active sparing of the intended surgical approach will be incorporated into the radiation plan by creating an avoidance structure. Surgical stabilization will proceed within 1 week of completion of radiotherapy. Pathologic specimens will be obtained intraoperatively via existing surgical access for histologic and molecular analysis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Preoperative Stereotactic Body Radiotherapy (SBRT)</intervention_name>
    <description>Target lesions will be treated with preoperative SBRT consisting of biologically effective dose (BED10) of 50.4 - 81.6 Gy delivered in either three fractions or a single fraction.</description>
    <arm_group_label>Preoperative Stereotactic Body Radiotherapy (SBRT)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of metastatic cancer with radiologic evidence of skeletal metastases&#xD;
&#xD;
          -  Treatment target involving humerus, radius, pelvis, sacrum, femur, or tibial diaphysis&#xD;
&#xD;
          -  Age at enrollment ≥18 years&#xD;
&#xD;
          -  Life expectancy &gt;3 months&#xD;
&#xD;
          -  Ability to tolerate radiation simulation and treatment with immobilization of involved&#xD;
             anatomic site&#xD;
&#xD;
          -  Surgical candidate, as determined by the treatment team&#xD;
&#xD;
          -  Able to undergo MRI scan&#xD;
&#xD;
          -  Ability to obtain informed consent from patient or legally authorized representative&#xD;
             in the setting of patient with impaired decision-making capacity.&#xD;
&#xD;
          -  Must agree to practice an effective contraceptive method (for those with reproductive&#xD;
             potential)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior radiotherapy to the treatment site&#xD;
&#xD;
          -  Prior surgery involving the treatment site&#xD;
&#xD;
          -  Tumor volume or distribution precluding effective SBRT&#xD;
&#xD;
          -  Expected skin dose at the operative site ≥9 Gy&#xD;
&#xD;
          -  Imminently impending fracture requiring immediate stabilization surgery&#xD;
&#xD;
          -  Involvement of proximal tibia&#xD;
&#xD;
          -  Autoimmune connective tissue disorder&#xD;
&#xD;
          -  Concomitant administration of radiosensitizing medication&#xD;
&#xD;
          -  Active infection&#xD;
&#xD;
          -  Absolute neutrophil count &lt;1.0&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maksim Vaynrub, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maksim Vaynrub, MD</last_name>
    <phone>212-639-7038</phone>
    <email>vaynrubm@mskcc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Meredith Bartelstein, MD</last_name>
    <phone>212-639-8684</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Basking Ridge</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <zip>07920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maksim Vaynrub, MD</last_name>
      <phone>212-639-7038</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Monmouth</name>
      <address>
        <city>Middletown</city>
        <state>New Jersey</state>
        <zip>07748</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maksim Vaynrub, MD</last_name>
      <phone>212-639-7038</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Bergen</name>
      <address>
        <city>Montvale</city>
        <state>New Jersey</state>
        <zip>07645</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maksim Vaynrub, MD</last_name>
      <phone>212-639-7038</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Commack</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maksim Vaynrub, MD</last_name>
      <phone>212-639-7038</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Westchester</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maksim Vaynrub, MD</last_name>
      <phone>212-639-7038</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center (All protocol activities)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Makskim Vaynrub, MD</last_name>
      <phone>212-639-7038</phone>
    </contact>
    <contact_backup>
      <last_name>Meredith Bartelstein, MD</last_name>
      <phone>212-639-8684</phone>
    </contact_backup>
    <investigator>
      <last_name>Maksim Vaynrub, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Nassau</name>
      <address>
        <city>Uniondale</city>
        <state>New York</state>
        <zip>11553</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maksim Vaynrub, MD</last_name>
      <phone>212-639-7038</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/mskcc/html/44.cfm</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 31, 2021</study_first_submitted>
  <study_first_submitted_qc>August 31, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 8, 2021</study_first_posted>
  <last_update_submitted>August 31, 2021</last_update_submitted>
  <last_update_submitted_qc>August 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Skeletal metastases</keyword>
  <keyword>Stereotactic Body Radiotherapy (SBRT)</keyword>
  <keyword>Surgical Stabilization</keyword>
  <keyword>Bone cancer</keyword>
  <keyword>21-216</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

